CENTURY THERAPEUTICS INC

CENTURY THERAPEUTICS INC (IPSC)

$3.18

+0.13

(+4.26%)

Market is closed - opens 7 PM, 01 Jun 2023

Insights on CENTURY THERAPEUTICS INC

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 2.97M → 1.72M (in $), with an average decrease of 42.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -100.18M → -31.26M (in $), with an average increase of 220.4% per quarter

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 43.0% return, outperforming this stock by 107.9%

Performance

  • $3.02
    $3.20
    $3.18
    downward going graph

    5.03%

    Downside

    Day's Volatility :5.63%

    Upside

    0.63%

    downward going graph
  • $2.81
    $14.00
    $3.18
    downward going graph

    11.64%

    Downside

    52 Weeks Volatility :79.93%

    Upside

    77.29%

    downward going graph

Returns

PeriodCENTURY THERAPEUTICS INCSector (Health Care)Index (Russel 2000)
3 Months
-32.37%
-0.3%
-6.7%
6 Months
-70.95%
-8.8%
-6.2%
1 Year
-64.9%
-4.2%
-5.1%
3 Years
-88.95%
23.0%
26.9%

Highlights

Market Capitalization
180.5M
Book Value
$4.69
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.01
Wall Street Target Price
18.3
Profit Margin
0.0%
Operating Margin TTM
-2192.05%
Return On Assets TTM
-15.96%
Return On Equity TTM
-37.56%
Revenue TTM
5.9M
Revenue Per Share TTM
0.1
Quarterly Revenue Growth YOY
62.6%
Gross Profit TTM
5.2M
EBITDA
-118.3M
Diluted Eps TTM
-2.01
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.09
EPS Estimate Next Year
-2.12
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 17 Wall street analysts offering stock ratings for CENTURY THERAPEUTICS INC(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
15
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 475.47%

Current $3.18
Target $18.30

Technicals Summary

Sell

Neutral

Buy

CENTURY THERAPEUTICS INC is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
CENTURY THERAPEUTICS INC
CENTURY THERAPEUTICS INC
-4.98%
-70.95%
-64.9%
-88.95%
-88.95%
Moderna, Inc.
Moderna, Inc.
-3.38%
-26.73%
-11.31%
107.29%
592.96%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.68%
-3.07%
9.61%
21.54%
142.61%
Seagen, Inc.
Seagen, Inc.
-2.59%
59.82%
42.99%
22.0%
220.73%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.71%
2.81%
21.09%
13.49%
111.23%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
CENTURY THERAPEUTICS INC
CENTURY THERAPEUTICS INC
45.5
NA
NA
-2.09
-0.38
-0.16
0.0
4.69
Moderna, Inc.
Moderna, Inc.
11.22
11.22
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.72
19.72
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.53
26.53
0.41
13.64
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
CENTURY THERAPEUTICS INC
CENTURY THERAPEUTICS INC
Buy
$180.5M
-88.95%
45.5
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.1B
592.96%
11.22
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
142.61%
19.72
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.3B
220.73%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$85.0B
111.23%
26.53
35.4%

Institutional Holdings

  • FMR Inc

    11.91%
  • Casdin Capital, LLC

    5.38%
  • BlackRock Inc

    2.44%
  • Dafna Capital Management LLC

    2.19%
  • Avidity Partners Management LP

    2.13%
  • Federated Hermes Inc

    1.95%

Company Information

Century Therapeutics, Inc. specializes in adult stem cells to develop curative cell therapy products for cancer that overcome the limitations of first generation cell therapies as well as provides testing and research services.

Organization
CENTURY THERAPEUTICS INC
Employees
163
CEO
Dr. Osvaldo Flores Ph.D.
Industry
Non-Energy Minerals

FAQs